TrialBlood cancer journal2026

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

Shaji Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.